Insulin icodec
- Generic Name
- Insulin icodec
- Brand Names
- Awiqli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1188379-43-2
- Unique Ingredient Identifier
- P7YU3ED05N
- Associated Conditions
- -
- Associated Therapies
- -
A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT03766854
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 247
- Registration Number
- NCT03751657
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT03723785
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT03723772
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT02964104
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT02148861
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT01809184
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath